Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

European equity markets trimmed losses on Friday with pharma stocks lower on news that Robert F. Kennedy Jr – who has made ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...

(Reuters) - Europe's STOXX 600 opened lower on Friday, dragged by technology and healthcare stocks, keeping the index on ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...